Author

N. Starling

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 3 Organism:human· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

D. Cunningham· 4 shared A. Woolston· 3 shared I. Chau· 3 shared L. J. Barber· 3 shared M. Gerlinger· 3 shared A. Sadanandam· 2 shared B. Griffiths· 2 shared D. Watkins· 2 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

D. Cunningham

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Context-specific GITR agonism potentiates anti-PD-L1 and CD40-based immuno- chemotherapy combination in heterogeneous pancreatic tumors

C. Ragulan, K. Desai, P. V. Lawrence, Y. Ikami, M. M. Aalam, H. Ps, N. Kannan, D. Cunningham, N. Starling, A. Sadanandam

This study identifies GITR agonism as a potential enhancer of anti-PD-L1 and CD40-based immunotherapy in pancreatic tumors by targeting immune evasion mechanisms.

bioRxiv · Jun 16, 2023 · PreprintCancer Biology

Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer

B. R. Challoner, A. Woolston, D. Lau, M. Buzzetti, C. Fong, L. J. Barber, G. Anandappa, R. Crux, I. Assiotis, K. Fenwick, R. Begum, D. Begum, T. Lund, N. Sivamanoharan, H. B. Sansano, , M. Gerlinger

The paper identifies three subtypes of MMR deficient colorectal cancer based on genetic and immune landscape evolution, linking them to T-cell infiltrates and checkpoint-inhibitor resistance.

bioRxiv · Feb 16, 2022 · PreprintCancer Biology

Mutational processes impact the evolution of anti-EGFR antibody resistance in colorectal cancer

A. Woolston, L. J. Barber, B. Griffiths, N. Matthews, S. Rao, D. Watkins, I. Chau, N. Starling, D. Cunningham, M. Gerlinger

The paper investigates mutational processes in colorectal cancer resistance to anti-EGFR antibodies, finding that mutational Signature 17 predicts resistance evolution and shorter progression-free survival.

bioRxiv · May 7, 2020Cancer Biology

Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer

A. Woolston, K. Khan, G. Spain, L. J. Barber, B. Griffiths, R. Gonzalez Exposito, Y. Patil, S. Mansukhani, M. N. Davies, A. Furness, F. Sclafani, C. Peckitt, K. Kouvelakis, R. Ranftl, R. Begum, , M. Gerlinger

The paper analyzes genomic and transcriptomic data from CRC patients treated with cetuximab to identify resistance mechanisms and immune landscape changes during anti-EGFR therapy.

bioRxiv · Oct 19, 2018Cancer Biology